Welcome to our dedicated page for IRIDEX SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRIDEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRIDEX's regulatory disclosures and financial reporting.
IRIDEX CORP (IRIX) reported an insider stock purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/17/2025, the reporting person bought 3,034 shares of common stock at a price of $0.96 per share and an additional 90 shares at $0.9569 per share in open-market transactions coded as purchases ("P").
Following these transactions, the reporting person beneficially owns 79,843 shares of IRIDEX common stock, held directly. The filing indicates that it is made by one reporting person and confirms the officer status as Chief Financial Officer.
IRIDEX Corporation reported an insider share purchase by its Chief Financial Officer. On 11/14/2025, the CFO acquired 14,769 shares of common stock in an open market purchase coded "P" at a price of $0.88 per share. Following this transaction, the officer beneficially owned 76,719 shares of IRIDEX common stock held directly. This type of report provides transparency about trading activity by senior management in the company’s equity.
IRIDEX (IRIX) reported Q3 2025 results showing total revenues of $12.484M, up from $11.581M a year ago. Gross profit was $4.013M versus $4.323M last year, with a loss from operations of $1.411M improving from $1.870M. Net loss narrowed to $1.573M from $1.933M, as operating expenses declined year over year.
By product, Retina delivered $6.698M and Cyclo G6 $3.537M. The United States contributed $5.588M; EMEA reached $4.033M. A key distributor, Topcon, accounted for 31% of Q3 revenues.
Cash and cash equivalents were $5.573M at quarter‑end (vs. $2.387M at December 28, 2024), aided by $6.0M of Series B convertible preferred stock and a $4.0M convertible note, partially offset by repayment of a prior note. The company recorded a year‑to‑date loss on extinguishment of debt of $1.335M and an inventory write‑down of $0.823M. Deferred revenue ended at $9.416M, including exclusivity fees recognized at $0.4M in Q3.
Total stockholders’ equity increased to $4.681M from $2.097M. Common shares outstanding were 17,189,981 as of November 6, 2025.
Patrick Mercer, President and CEO of IRIDEX CORP (IRIX), reported a sale of 23,850 shares on 10/01/2025 at a reported price of $1.13 per share. After the transaction Mercer beneficially owns 392,007 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 09/12/2025. The Form 4 shows two non-derivative acquisitions: 250 shares at $1.37 and 1,200 shares at $1.36, for a total of 1,450 shares acquired. Following the transactions, the filing reports 61,950 shares beneficially owned. The form is signed by an attorney-in-fact on 09/15/2025.
Romeo R. Dizon, the Chief Financial Officer and a director of Iridex Corp (IRIX), reported insider purchases on 09/10/2025. He acquired 1,000 shares at $1.33 and 500 shares at $1.36, bringing his total reported beneficial ownership to 59,250 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025.
Iridex Corp (IRIX) insider purchase: Chief Financial Officer Romeo R. Dizon purchased 1,500 shares of Iridex common stock on 09/09/2025 at a price of $1.37 per share. Following the transaction, the reporting person beneficially owns 57,750 shares. The Form 4 was filed indicating the transaction code "P" and was signed by an attorney-in-fact on 09/10/2025.
IRIDEX Corporation reports that it has regained compliance with Nasdaq’s continued listing standards. Based on its Form 10-Q for the quarter ended June 28, 2025, the company now meets the Nasdaq Listing Rule 5550(b)(1) minimum stockholders’ equity requirement of $2,500,000 for the Nasdaq Capital Market.
Nasdaq has informed IRIDEX that the prior non-compliance matter is closed, removing the earlier listing deficiency. The company also issued a press release on September 9, 2025 to highlight its renewed compliance with the stockholders’ equity requirement.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported an insider purchase of common stock. On 09/08/2025 he acquired 500 shares at $1.40 per share, increasing his reported beneficial ownership to 56,250 shares. The Form 4 was signed on 09/09/2025 by an attorney-in-fact.
Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.